New hope for hepatitis d: libevitug enters final testing phase
NCT ID NCT07499544
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing a new drug called libevitug in 160 people with chronic hepatitis D, a serious liver infection. The goal is to see if libevitug can lower the virus in the blood and improve liver health. Participants receive the drug by IV infusion, and the study compares different doses to find the best approach.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- libevitug
- What this could lead to
- If it works, this could offer a new treatment option to control chronic hepatitis D, reducing virus levels and improving liver function.
- What could go wrong
- This is an early Phase 3 trial with only 160 participants. The drug may not work for everyone, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HDV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
RECRUITINGChangchun, Jilin, 130033, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a daily pill tame hepatitis d?
- New combo therapy aims to clear hepatitis b and d in 20-patient trial
- New antibody could tame dual hepatitis b and d infection
- New hope for hepatitis delta: phase 3 trial of brelovitug launches
- Liver drug bulevirtide tested in people with liver problems
- New drug bulevirtide tracked in real-world hepatitis d patients